Published in Drug Week, November 17th, 2006
In this trial, investigators will assess the efficacy, safety and tolerability of Avicena's proprietary ALS-08 drug candidate in separate combinations with minocycline and celecoxib (a COX-2 inhibitor).
"Completion of patient enrollment for this stage is an important step in the advancement of our clinical drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.